GAMP 5 Category 4 compliance with a remote workforce: How to do it - Sirus case study
Good practice (GxP) guidelines help businesses make products that are safe and fit for use. Read about the various requirements and how they protect quality.
How does EQMS help you to comply with FDA title 21 CFR Part 11? This article details exactly how and why EQMS helps you to comply.
What do you do when a hard Brexit stands in the middle of your time-sensitive and high-value supply chain? We asked one of our customers.
BAP Pharma sources medicinal products from around the world. That means due diligence, strict quality control and consistent best practice. BAP Pharma's Head of Quality explains how EQMS by Qualsys became a 'second person' supporting his goals.
Qualsys's Chris Owen reviews the GAMP CoP event.
The flexibility of Qualsys's software solution allows customers to apply their own ideas and initiatives. We asked Sirus Quality, Training & Health/Safety Manager Pauline Sourdille how she uses the system day-to-day.
We asked three of our customers to share their insights and advice for building a life science electronic quality management system. See their responses here.
Sodexo's EQMS Manager Rob Gibson explains why his pharmaceutical clients are 'raving' about Qualsys's software solution.
Medical laboratories have until September 2018 to transition from CPA accreditation to ISO 15189. We created a gap analysis to help you pinpoint what to change, and where.
We asked our life science readers to share their tips and insights for quality management in one of the world's most challenging sectors. Read their thoughts here.
ISO 17025 is the international standard for testing and calibration laboratories. Learn what the standard involves and how EQMS helps meet the requirements.
The Quality Context is hosting the first ever annual training conference. The conference is a mus-attend for quality professionals in the pharmaceuticals industry.
Qualsys attend the ISPE GAMP Forum, an event aiming to increase dialogue and practical guidance between those involved in pharmaceutical regulation.
Obamacare is set to create a $350 billion bonanza for Indian and Chinese Pharmaceutical Manufacturers.